http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107699565-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107699565-B |
| titleOfInvention | Micro RNA and application thereof in preparation of antitumor drugs |
| abstract | The invention relates to the technical field of biological pharmacy, in particular to micro RNA and application thereof in preparing antitumor drugs. The RNA molecule provided by the invention is characterized in that any one base in 10 th to 22 th positions of the 5' end of a miR-34a sequence is mutated into n, wherein the n is A, C, G or U; the RNA molecule and the complementary strand thereof can inhibit the protein levels of PD-L1, B7-H3, B7-H4 and the like in tumor cells, and inhibit the growth and/or proliferation of the tumor cells, thereby playing the role of resisting tumors. Moreover, research shows that the microRNA provided by the invention has no significant influence on the secretion of cytokines in serum while resisting tumors. |
| priorityDate | 2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 374.